Phase 2
Completed N=100
Modeling Stress-precipitated Smoking Behavior for Medication Development
Source: ClinicalTrials.gov NCT00773357 ↗Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Aug 2022
Primary outcomePrimary: Latency to Initiate Ad-lib Smoking Session — 31.55; 30.31 minutes
Summary
The purpose of this study is to examine whether guanfacine will attenuate the ability of stress to precipitate smoking lapse behavior in treatment seeking and non-treatment seeking daily smokers.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Latency to Initiate Ad-lib Smoking Session |
31.55; 30.31 | — |
Eligibility Criteria
Inclusion Criteria
- ages 18-60
- able to read and write in English
- smokers
Exclusion Criteria
- any significant current medical conditions that would contraindicate smoking
- current Diagnostic and Statistical Manual IV (DSM-IV) abuse or dependence of other substances, other than nicotine (or caffeine) dependence
- positive test result at intake appointments on urine drug screens conducted for opiates, cocaine, or benzodiazepines
- women who are pregnant or nursing
- suicidal, homicidal or evidence of severe mental illness
- participants prescribed any psychotropic drug in the 30 days prior to study enrollment
- blood donation within the past 6 weeks
- participants who have engaged in a quit attempt in the past 3 months
- specific exclusions for administration of guanfacine not already specified include: Hypotensive individuals with sitting blood pressure below 90/50 mmHG; EKG evidence at baseline screening of any clinically significant conduction abnormalities, including a Bazett's corrected QT interval (QTc) >450 msec for men and QTc>470 msec for women; known intolerance for guanfacine
Data sourced from ClinicalTrials.gov (NCT00773357). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.